Peptide–Antibody Fusions Engineered by Phage Display Exhibit an Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants
- 22 June 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 17 (7) , 1978-1988
Abstract
The spread of COVID-19 has been exacerbated by the emergence of variants of concern (VoC). Many VoC contain mutations in the spike protein (S-protein) and are implicated in infection and response to therapeutics. Bivalent neutralizing antibodies (nAbs) targeting the S-protein receptor-binding domain (RBD) are promising therapeutics for COVID-19, but they are limited by low potency and vulnerability to RBD mutations in VoC. To address these issues, we used naïve phage-displayed peptide libraries to isolate and optimize 16-residue peptides that bind to the RBD or the N-terminal domain (NTD) of the S-protein. We fused these peptides to the N-terminus of a moderate-affinity nAb to generate tetravalent peptide-IgG fusions, and we showed that both classes of peptides were able to improve affinities for the S-protein trimer by >100-fold (apparent KD < 1 pM). Critically, cell-based infection assays with a panel of six SARS-CoV-2 variants demonstrated that an RBD-binding peptide was able to enhance the neutralization potency of a high-affinity nAb >100-fold. Moreover, this peptide-IgG was able to neutralize variants that were resistant to the same nAb in the bivalent IgG format, including the dominant B.1.1.529 (Omicron) variant that is resistant to most clinically approved therapeutic nAbs. To show that this approach is general, we fused the same peptide to a clinically approved nAb drug and showed that it enabled the neutralization of a resistant variant. Taken together, these results establish minimal peptide fusions as a modular means to greatly enhance affinities, potencies, and breadth of coverage of nAbs as therapeutics for SARS-CoV-2.Keywords
All Related Versions
Funding Information
- Canadian Institutes of Health Research (OV3-170649)
- Regione Lazio
- Canada Foundation for Innovation (IOF-33363)
- Rome Foundation (317A / I)
- Mercatus Center FAST (2161, 2189)
- Ministero dell'Istruzione, dell'Università e della Ricerca (FISR2020IP_03161)
This publication has 37 references indexed in Scilit:
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-OncologyClinical Cancer Research, 2019
- Quantitative Systems Pharmacology Model of a Masked, Tumor‐Activated AntibodyCPT: Pharmacometrics & Systems Pharmacology, 2019
- Biophysical properties of the clinical-stage antibody landscapeProceedings of the National Academy of Sciences, 2017
- Rapid isolation of peptidic inhibitors of the solute carrier family transporters OATP1B1 and OATP1B3 by cell-based phage display selectionsBiochemical and Biophysical Research Communications, 2016
- Probody therapeutics for targeting antibodies to diseased tissueExpert Opinion on Biological Therapy, 2014
- Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic IndexScience Translational Medicine, 2013
- Identifying specificity profiles for peptide recognition modules from phage-displayed peptide librariesNature Protocols, 2007
- Vpr-mediated Incorporation of UNG2 into HIV-1 Particles Is Required to Modulate the Virus Mutation Rate and for Replication in MacrophagesJournal of Biological Chemistry, 2004
- The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core ComplexJournal of Virology, 2003